Peroxisome proliferator-activated receptor-γ C190S mutation causes partial lipodystrophy

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 6, 2007, Pages 2248-2255

  Lüdtke, Angelika ^a,b   Buettner, Janine ^b   Wu, Wei ^a   Muchir, Antoine ^a   Schroeter, Andreas ^c   Zinn Justin, Sophie ^d   Spuler, Simone ^b   Schmidt, Hartmut H J ^b,e   Worman, Howard J ^a  

^a Columbia University ^*  (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Diabetesnetz Kraichgau Nord   (Germany)

^d CEA SACLAY   (France)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ADULT; ARTICLE; BODY COMPOSITION; CONTROLLED STUDY; DNA BINDING; FATTY LIVER; FEMALE; GEL MOBILITY SHIFT ASSAY; HUMAN; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; REPORTER GENE; STATISTICAL SIGNIFICANCE; TRANSCRIPTION INITIATION; WILD TYPE;

EID: 34347224036     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-2624     Document Type: Article

References (46)

1. Cao H, Hegele RA 2000 Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet 9:109-112
2. Shackleton S, Lloyd DJ, Jackson SN, Evans R, Niermeijer MF, Singh BM, Schmidt H, Brabant G, Kumar S, Durrington PN, Gregory S, O'Rahilly S, Trembath RC 2000 LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet 24:153-156
3. Speckman RA, Garg A, Du F, Bennett L, Veile R, Arioglu E, Taylor SI, Lovett M, Bowcock AM 2000 Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A/C. Am J Hum Genet 66:1192-1198
4. Garg A 2004 Acquired and inherited lipodystrophies. N Engl J Med 350:1220-1234
5. Schmidt HH, Genschel J, Baier P, Schmidt M, Ockenga J, Tietge UJ, Propsting M, Buttner C, Manns MP, Lochs H, Brabant G 2001 Dyslipidemia in familial partial lipodystrophy caused by an R482W mutation in the LMNA gene. J Clin Endocrinol Metab 86:2289-2295
6. Ludtke A, Genschel J, Brabant G, Bauditz J, Taupitz M, Koch M, Wermke W, Worman HJ, Schmidt HH 2005 Hepatic steatosis in Dunnigan-type familial partial lipodystrophy. Am J Gastroenterol 100:2218-2224
7. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S 1999 Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402:880-883
8. Hegele RA, Cao H, Frankowski C, Mathews ST, Leff T 2002 PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes 51:3586-3590
9. Argawal AK, Garg A 2002 A novel heterozygous mutation in peroxisome proliferator-activated receptor-γ gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab 87:408-411
10. Al-Shali K, Cao H, Knoers N, Hermus AR, Tack CJ, Hegele RA 2004 A single-base mutation in the peroxisome proliferator-activated receptor γ4 promoter associated with altered in vitro expression and partial lipodystrophy. J Clin Endocrinol Metab 89:5655-5660
11. Francis GA, Li G, Casey R, Wang J, Cao H, Leff T, Hegele RA 2006 Peroxisomal proliferator activated receptor-γ deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). BMC Med Genet 7:3
12. Hegele RA, Ur E, Ransom TP, Cao H 2006 A frameshift mutation in peroxisome-proliferator-activated receptor-γ in familial partial lipodystrophy subtype 3 (FPLD3; MIM 604367). Clin Genet 70:360-362
13. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W 1992 Control of the peroxisomal -oxidation pathway by a novel family of nuclear hormone receptors. Cell 68:879-887
14. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM 1994 Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 91:7355-7359
15. Reddy JK, Hashimoto T 2001 Peroxisomal β-oxidation and peroxisome proliferator-activated receptor α: an adaptive metabolic system. Annu Rev Nutr 21:193-230
16. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM 2003 Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell 113:159-170
17. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM, Mortensen RM 1999 PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4:611-617
18. Kota BP, Huang TH, Roufogalis BD 2005 An overview on biological mechanisms of PPARs. Pharmacol Res 51:85-94
19. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM 1992 Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358:771-774
20. Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, Green S 1992 The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J 11:433-439
21. Freedman LP, Luisi BF, Korszun ZR, Basavappa R, Sigler PB, Yamamoto KR 1988 The function and structure of the metal coordination sites within the glucocorticoid receptor DNA binding domain. Nature 334:543-546
22. Temple KA, Cohen RN, Wondisford SR, Yu C, Deplewski D, Wondisford FE 2005 An intact DNA-binding domain is not required for peroxisome proliferator-activated receptor γ (PPARγ) binding and activation on some PPAR response elements. J Biol Chem 280:3529-3540
23. Elbrecht A, Chen Y, Cullinan CA, Hayes N, Leibowitz M, Moller DE, Berger J 1996 Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors γ1 and γ2. Biochem Biophys Res Commun 224:431-437
24. Fajas L, Fruchart JC, Auwerx J 1998 PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter. FEBS Lett 438:55-60
25. Sundvold H, Lien S 2001 Identification of a novel peroxisome proliferatoractivated receptor (PPAR) γ promoter in man and transactivation by the nuclear receptor RORα1. Biochem Biophys Res Commun 287:383-390
26. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J 1997 The organization, promoter analysis, and expression of the human PPARγ gene. J Biol Chem 272:18779-18789
27. Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M, Atherton J, Vidaillet Jr HJ, Spudich S, De Girolami U, Seidman JG, Seidman C, Muntoni F, Muehle G, Johnson W, McDonough B 1999 Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 341:1715-1724
28. Schaffer AA, Aravind L, Madden TL, Shavirin S, Spouge JL, Wolf YI, Koonin EV, Altschul SF 2001 Improving the accuracy of PSI-BLAST protein database searches with composition-based statistics and other refinements. Nucleic Acids Res 29:2994-3005
29. DeLano WL 2002 The PyMOL Molecular Graphics System. San Carlos, CA: DeLano Scientific LLC (http://www.pymol.org)
30. Collingwood TN, Adams M, Tone Y, Chatterjee VKK 1994 Spectrum of transcriptional dimerization and dominant negative properties of twenty different mutant thyroid hormone β receptors in thyroid hormone resistance syndrome. Mol Endocrinol 8:1262-1277
31. Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VK 1997 Transcriptional activation by peroxisome proliferator-activated receptor γ is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem 272:5128-5132
32. Devine JH, Eubank DW, Clouthier DE, Tontonoz P, Spiegelman BM, Hammer RE, Beale EG 1999 Adipose expression of the phosphoenolpyruvate carboxykinase promoter requires peroxisome proliferator-activated receptor γ and 9-cis-retinoic acid receptor binding to an adipocyte-specific enhancer in vivo. J Biol Chem 274:13604-13612
33. Graves RA, Tontonoz P, Platt KA, Ross SR, Spiegelman BM 1992 Identification of a fat cell enhancer: analysis of requirements for adipose tissue-specific gene expression. J Cell Biochem 49:219-224
34. Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, Shimomura I 2003 Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52:1655-1663
35. Schoonjans K, Staels B, Auwerx J 1996 Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37:907-925
36. Laffitte BA, Joseph SB, Walczak R, Pei L, Wilpitz DC, Collins JL, Tontonoz P 2001 Autoregulation of the human liver X receptor α promoter. Mol Cell Biol 21:7558-7568
37. Perera RJ, Marcusson EG, Koo S, Kang X, Kim Y, White N, Dean NM 2006 Identification of novel PPARγ target genes in primary human adipocytes. Gene 369:90-99
38. Frisancho AR 1981 New norms of upper limb fat and muscle areas for assessment of nutritional status. Am J Clin Nutr 34:2540-2545
39. Ijpenberg A, Jeannin E, Wahli W, Desvergne B 1997 Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element. J Biol Chem 272:20108-20117
40. Schwabe JW, Neuhaus D, Rhodes D 1990 Solution structure of the DNA-binding domain of the oestrogen receptor. Nature 348:458-461
41. Savage DB, Agostini M, Barroso I, Gurnell M, Luan J, Meirhaeghe A, Harding AH, Ihrke G, Rajanayagam O, Soos MA, George S, Berger D, Thomas EL, Bell JD, Meeran K, Ross RJ, Vidal-Puig A, Wareham NJ, O'Rahilly S, Chatterjee VK, Schafer AJ 2002 Digenic inheritance of severe insulin resistance in a human pedigree. Nat Genet 31:379-384
42. Reitman ML, Arioglu E, Gavrilova O, Taylor SI 2000 Lipoatrophy revisited. Trends Endocrinol Metab 11:410-416
43. Hegele RA, Anderson CM, Wang J, Jones DC, Cao H 2000 Association between nuclear lamin A/C R482Q mutation and partial lipodystrophy with hyperinsulinemia, dyslipidemia, hypertension, and diabetes. Genome Res 10:652-658
44. Hegele RA, Kraw ME, Ban MR, Miskie BA, Huff MW, Cao H 2003 Elevated serum C-reactive protein and free fatty acids among nondiabetic carriers of missense mutations in the gene encoding lamin A/C (LMNA) with partial lipodystrophy. Arterioscler Thromb Vasc Biol 23:111-116
45. Agostini M, Schoenmakers E, Mitchell C, Szatmari I, Savage D, Smith A, Rajanayagam O, Semple R, Luan J, Bath L, Zalin A, Labib M, Kumar S, Simpson H, Blom D, Marais D, Schwabe J, Barroso I, Trembath R, Wareham N, Nagy L, Gurnell M, O'Rahilly S, Chatterjee K 2006 Non-DNA binding, dominant-negative, human PPARγ mutations cause lipodystrophic insulin resistance. Cell Metab 4:303-311
46. Monajemi H, Zhang L, Li G, Jeninga EH, Cao H, Maas M, Brouwer CB, Kalkhoven E, Stroes E, Hegele RA, Leff T 2007 Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor γ. J Clin Endocrinol Metab 92:1606-1612